Julian Adams named chief science officer of SU2C

SU2C, Johnson & Johnson collaborate on research project focused on rare disease linked to blood cancers

Stand Up To Cancer and Johnson & Johnson announced a collaboration aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to treat a rare disease called AL amyloidosis.

November 15, 2024

Vol.50 No.43

In Brief

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

In Brief

William Nelson named chair of the SU2C scientific advisory committee

Nobel laureate Phillip A. Sharp, who has chaired the Stand Up To Cancer scientific advisory committee since SU2C launched in 2008 is transitioning to emeritus status at the organization.

February 09, 2024

Vol.50 No.06

In Brief

Julian Adams named CEO, president of Stand Up To Cancer

Julian Adams was named president and CEO of Stand Up To Cancer.

December 15, 2023

Vol.49 No.46

In Brief

SU2C announces three research teams to study gastroesophageal cancer

Stand Up To Cancer has announced three Research Teams focused on bringing new therapies to clinical trials for the treatment of gastroesophageal cancer.

November 17, 2023

Vol.49 No.43

In Brief

SU2C recognized by CHOP and SITC for support of cancer research

Stand Up To Cancer was recognized by Children’s Hospital of Philadelphia and the Society for Immunotherapy of Cancer for the contributions and achievements SU2C has made in raising funds and awareness to help cancer research.

November 03, 2023

Vol.49 No.41

Julian Adams named chief science officer of SU2C

YOU MAY BE INTERESTED IN

SU2C, Johnson & Johnson collaborate on research project focused on rare disease linked to blood cancers

SU2C announces grants supporting research in six cancer types

William Nelson named chair of the SU2C scientific advisory committee

Julian Adams named CEO, president of Stand Up To Cancer

SU2C announces three research teams to study gastroesophageal cancer

SU2C recognized by CHOP and SITC for support of cancer research

Renew today!

Subscriber content

Never miss an issue!

Login